Refine by
Cardiac Arrest A New Device Articles & Analysis
27 news found
Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has joined the Amazon Web Services (AWS) Independent Software Vendor (ISV) Accelerate Program, a co-sell program for AWS partners that provide software solutions that run on or integrate with AWS. The program helps AWS partners drive new business by directly connecting participating ISCs with the ...
Valo Health, Inc (“Valo”) shared the initial results of a collaborative study with the U.S. Food and Drug Administration (FDA), demonstrating the potential of Valo’s Biowire platform to predict clinical efficacy of Cardiac Contractility Modulation ...
Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced a significant milestone of recording and analyzing over 2 billion heartbeats for Atrial Fibrillation (AFib), the most common type of cardiac arrhythmia and a leading cause of stroke. Bioflux®, Biotricity’s ...
Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced that it will be carrying out an NIH-sponsored Phase I study of Bioflux-AI, Biotricity’s innovative artificial intelligence-driven (‘AI’) system of real-time monitoring and prediction technology, in subjects with ...
iRhythm Technologies has presented new data on its Zio wearable cardiac monitoring device at the American College of Cardiology (ACC) 71st Annual Scientific Session & Expo, building the clinical case for its devices. One study used Zio AT for monitoring patients who were taken to hospital after fainting. By using the device to monitor patients after discharge, the physicians reduced ...
Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, will officially launch the commercial sales of its FDA cleared, wireless wearable cardiac monitoring device, Biotres, in April 2022. The product has been available for pre-orders to physicians, medical offices, hospitals and individual use since ...
Like many people with atrial fibrillation (AFib), Sheldon Kittelson of Clarkfield, Minnesota, felt trapped between the fear of having a stroke and the fear of spending a lifetime on blood thinners. For people with AFib, blood doesn’t flow through the heart normally, which can result in a clot forming in the left atrial appendage (LAA) that can break loose and lead to a stroke. ...
Announcement follows FDA clearance Pre-Orders begin on February 23, 2022 with units shipping April 1, 2022 Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced that it is now taking pre-orders for Biotres, the Company’s three-lead device designed to continuously record ...
Biotres is designed to continuously record ECG data for early detection of cardiac arrhythmias The Biotres addresses the $2 Billion-dollar holter market Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today reported it has received 510(k) clearance from the U.S. Food and Drug ...
EBR Systems’ WiSE™ CRT System is world’s first and only wireless endocardial (inside the heart) left ventricle pacing system for heart failure EBR’s AU$110m ASX initial public offering today was strongly supported by new and existing institutional shareholders The new capital funds the completion of pivotal study, targeting FDA submission for approval in 2023 followed ...
Highlights: Dr Evans, Dr Steinhaus and Ms Drexler to join EBR Systems’ Board ahead of the planned A$110m IPO on the Australian Stock Exchange Board appointments follow the retirement of Mr Dave Stassen and Dr Leighton Read New EBR Systems’ Board consists of Mr Allan Will, Mr John McCutcheon, Dr Christopher Nave, Mr Trevor Moody, Dr Bronwyn Evans, Dr David Steinhaus and Ms ...
CorWave, a French medtech developing a next-generation heart pump, is recruiting top talent from throughout the world to strengthen its team. Two seasoned industry experts are joining the company: Paul Cornelison (USA) as Vice President, Regulatory Affairs, Quality Assurance and Clinical Affairs, and Michael Webb (Australia) as Vice President, Manufacturing. Paul Cornelison and Michael Webb have ...
ByCorWave
CorWave announced that it successfully completed its first 60-day preclinical study to evaluate its Left Ventricular Assist Device (LVAD). The results were presented at the 46th Annual Conference of the European Society for Artificial Organs (ESAO) in Hannover. Trevor Snyder, PhD, Senior Director, Translational and Clinical Research at CorWave, delivered an oral presentation, “CorWave ...
ByCorWave
South Korean artificial intelligence (AI) developer, VUNO Inc. announced today that it has received regulatory approval from the Ministry of Food and Drug Safety (MFDS) for its VUNO Med®–DeepCARS™, an AI medical device for cardiac arrest prediction through vital signs. VUNO Med®–DeepCARS™ is a breakthrough AI-driven medical device that analyzes the potential risk ...
A dual-center study reported that vMap™, as part of a new, non-invasive workflow - with Varian’s CRA system - improved efficiency and precision for radio-ablation therapy in these study subjects. The study showed that the radio-ablation administered as a part of the enhanced workflow also significantly reduced ICD shocks for patients receiving the therapy. Presented by its lead ...
Bluegrass Vascular Technologies, a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced today the publication of a report documenting the clinical utility of the Surfacer System to gain venous access prior to the placement of cardiac resynchronization therapy (CRT) device leads in a patient with obstructed central veins. ...
Addressable market in the bridge-to-transplant indication of more than 2,000 patients a year in Europe Company prepares for commercial launch in Q2 2021, with initial focus on Germany and France Robust clinical plan to support adoption and sales development Virtual conference with Stéphane Piat today at 5 pm CET CARMAT (FR0010907956, ALCAR), the designer and developer of the ...
ByCarmat
KEY POINTS Cardiac arrest is one of the leading causes of death in the U.S. and globally. It has a survival rate of 1 in 10 people with current treatment. The Neurescue device is designed to increase blood flow to the brain and heart during life-threatening emergencies such as cardiac arrest. ...
For the very first time, AdjuCor GmbH's revolutionary new heart-assist technology – BEAT – will take the stage at the prestigious 41st International Society for Heart and Lung Transplantation (#ISHLT2021). Prof. Ulrich Stock will be presenting BEAT’s acute and chronic preclinical results, proudly showcasing this first-in-class technology and how it can assist the failing heart. ...
BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter Ventricular Restoration (TCVR), today announced that Chris Wolff has been named Vice President of U.S. Sales. In this role, Mr. Wolff will be responsible for driving enrollment in the ongoing ALIVE Trial studying the Company’s Revivent TC Transcatheter Ventricular ...